TY - JOUR
TI - Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
AU - Terpos, E.
AU - Kostopoulos, I.V.
AU - Kastritis, E.
AU - Ntanasis-Stathopoulos, I.
AU - Migkou, M.
AU - Rousakis, P.
AU - Argyriou, A.T.
AU - Kanellias, N.
AU - Fotiou, D.
AU - Eleutherakis-Papaiakovou, E.
AU - Gavriatopoulou, M.
AU - Ziogas, D.C.
AU - Papanota, A.-M.
AU - Spyropoulou-Vlachou, M.
AU - Trougakos, I.P.
AU - Tsitsilonis, O.E.
AU - Paiva, B.
AU - Dimopoulos, M.A.
JO - Hemasphere
PY - 2019
VL - 3
TODO - 6
SP - null
PB - Ovid Technologies (Wolters Kluwer Health)
SN - null
TODO - 10.1097/HS9.0000000000000300
TODO - bortezomib;  daratumumab;  immunoglobulin A;  immunoglobulin D;  immunoglobulin G;  melphalan, adult;  aged;  Article;  B lymphocyte subpopulation;  bone marrow biopsy;  controlled study;  disease association;  drug megadose;  erythroblast;  female;  flow cytometry;  follow up;  high throughput sequencing;  human;  maintenance therapy;  major clinical study;  male;  middle aged;  minimal residual disease;  multiple myeloma;  phenotype;  priority journal;  prospective study;  treatment duration;  tumor diagnosis;  tumor volume
TODO - Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10-5; 17% at 10-6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10-6. © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
ER -